Protocol for Early Vyvanse Refill Request Due to Reported Loss
Do not provide an early refill for lost Vyvanse without thorough documentation and assessment for diversion, misuse, or addiction risk, as this is a Schedule II controlled substance with high abuse potential. 1
Immediate Assessment Steps
When a patient requests an early refill claiming lost medication, you must:
1. Check the Prescription Drug Monitoring Program (PDMP)
- Review for multiple prescribers, early refills from other sources, or patterns suggesting diversion
- Most states now mandate PDMP participation for controlled substances 2
- Document your PDMP review in the medical record
2. Assess for Signs of Misuse, Abuse, or Diversion
The FDA label explicitly warns that Vyvanse has high potential for abuse and misuse and requires ongoing monitoring for signs of substance use disorder 1. Look for:
- Frequency of "lost" medication claims (any prior episodes?)
- Requests for early refills without legitimate explanation
- Running out of medication early on multiple occasions
- Evidence the patient is selling, sharing, or trading medication
- Signs of escalating doses or using medication in unapproved ways
- Behavioral changes suggesting stimulant misuse
3. Document the Circumstances
Record specific details:
- When and how the medication was lost
- Whether a police report was filed (for theft/loss)
- Patient's explanation and demeanor
- Any inconsistencies in their story
- Previous similar requests
Decision Algorithm
If This is the First Reported Loss AND PDMP is Clear:
- Consider a one-time exception with strict documentation
- Provide only enough medication to bridge to the next scheduled refill date (not a full month)
- Document this is a one-time courtesy and future losses will not be replaced
- Counsel on secure storage requirements 1
- Consider switching to a non-stimulant alternative (atomoxetine, extended-release guanfacine/clonidine) to minimize abuse potential 2
If There is Any Prior History of Lost Medication OR Concerning PDMP Findings:
- Deny the early refill
- Explain that controlled substance regulations and safety concerns prevent replacement of lost medication
- Offer non-stimulant alternatives for the interim period
- Schedule an urgent follow-up visit to reassess treatment plan and discuss medication security
If Signs of Diversion or Substance Use Disorder are Present:
- Deny the refill immediately
- Refer to addiction medicine or psychiatry for substance use evaluation 2
- Consider discontinuing stimulant therapy
- Transition to non-stimulant ADHD medications (atomoxetine, extended-release guanfacine, extended-release clonidine) which have minimal abuse potential 2
Critical Pitfalls to Avoid
Do not reflexively provide replacement medication simply because the patient is distressed or insistent. The FDA explicitly requires prescribers to "reassess each patient's risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms" throughout treatment 1. An early refill request is precisely the type of event that should trigger heightened scrutiny.
Adolescents require special vigilance as diversion is a particular concern in this age group—they may share with or sell to classmates 2. The guideline specifically notes that clinicians should "monitor the adolescent's symptoms and prescription refill requests for signs of misuse or diversion."
Document everything meticulously. Your medical record should reflect your clinical reasoning, PDMP review, assessment for substance use disorder, and the specific rationale for your decision. This protects both patient safety and your medical license.
Alternative Management Strategy
If you determine the patient has legitimate ADHD requiring treatment but the early refill request raises concerns:
- Switch to a long-acting, lower-abuse-potential medication such as atomoxetine or extended-release guanfacine 2
- Implement more frequent follow-up visits with pill counts
- Require the patient to pick up smaller quantities more frequently (weekly instead of monthly)
- Involve family members in medication storage and administration when appropriate
The guideline emphasizes that for patients with substance use concerns, non-stimulant medications should be strongly considered to minimize abuse potential 2.